Hoots Brooke E, Finlayson Teresa J, Broz Dita, Paz-Bailey Gabriela
Division of HIV/AIDS Prevention, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, GA.
J Acquir Immune Defic Syndr. 2017 Jul 1;75 Suppl 3(Suppl 3):S392-S396. doi: 10.1097/QAI.0000000000001416.
Approximately 16% of infections among those living with diagnosed HIV infection in the United States are attributable to injection drug use. Antiretrovirals (ARVs) are recommended for all infected persons to improve health and prevent transmission. Using data from National HIV Behavioral Surveillance, we evaluated changes in ARV use from 2009 to 2015 among HIV-positive people who inject drugs (PWID).
PWID were recruited by respondent-driven sampling in 20 cities. ARV use was defined as self-reported use at the time of interview. Prevalence ratios measuring change in ARV use per 3-year increase in year were estimated using log-linked Poisson regression models with generalized estimating equations.
ARV use was 58% (319/548) in 2009, 67% (410/608) in 2012, and 71% (386/545) in 2015. In all 3 cycle years, a higher percentage of ARV treatment was observed among males, PWID of older age (≥50), and PWID with current health insurance. ARV use increased overall, with an adjusted relative increase of 8% per every 3-year increase in year (adjusted prevalence ratio 1.08, 95% confidence interval: 1.03 to 1.12). ARV use also increased among most subgroups.
These findings show progress in ARV treatment, although ARV coverage remains low compared with other populations at risk for HIV. Efforts to improve ARV coverage among PWIDs are needed.
在美国,确诊感染艾滋病毒的人群中,约16%的感染归因于注射吸毒。建议所有感染者使用抗逆转录病毒药物(ARV)以改善健康状况并预防传播。利用国家艾滋病毒行为监测的数据,我们评估了2009年至2015年期间注射毒品的艾滋病毒阳性者(PWID)中ARV使用情况的变化。
通过应答者驱动抽样在20个城市招募PWID。ARV使用定义为访谈时的自我报告使用情况。使用带有广义估计方程的对数链接泊松回归模型估计每3年年份增加时ARV使用变化的患病率比。
2009年ARV使用率为58%(319/548),2012年为67%(410/608),2015年为71%(386/545)。在所有3个周期年份中,男性、年龄较大(≥50岁)的PWID以及目前有医疗保险的PWID中观察到更高比例的ARV治疗。ARV使用总体上有所增加,每3年年份增加调整后的相对增加率为8%(调整后的患病率比1.08,95%置信区间:1.03至1.12)。大多数亚组中的ARV使用也有所增加。
这些发现表明ARV治疗取得了进展,尽管与其他艾滋病毒高危人群相比,ARV覆盖率仍然较低。需要努力提高PWID中的ARV覆盖率。